UA94052C2 - Похідні піридазину - Google Patents

Похідні піридазину

Info

Publication number
UA94052C2
UA94052C2 UAA200801149A UAA200801149A UA94052C2 UA 94052 C2 UA94052 C2 UA 94052C2 UA A200801149 A UAA200801149 A UA A200801149A UA A200801149 A UAA200801149 A UA A200801149A UA 94052 C2 UA94052 C2 UA 94052C2
Authority
UA
Ukraine
Prior art keywords
pyridazine derivatives
esters
compounds
formula
pharmaceutically acceptable
Prior art date
Application number
UAA200801149A
Other languages
English (en)
Russian (ru)
Inventor
Курт Амрайн
Даніель Хунцікер
Бернд Кун
Александер В. Майвег
Вернер НАЙДХАРТ
Original Assignee
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36781523&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA94052(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ф. Хоффманн-Ля Рош Аг filed Critical Ф. Хоффманн-Ля Рош Аг
Publication of UA94052C2 publication Critical patent/UA94052C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/28—Cinnolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

У заявці описані сполуки формули EMBED ISISServer , (I) а також їх фармацевтично прийнятні солі й складні ефіри, у якій R1-R4 мають значення, вказані в пункті 1 формули винаходу, які можна застосовувати у вигляді фармацевтичних композицій.
UAA200801149A 2005-07-05 2006-06-26 Похідні піридазину UA94052C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05106098 2005-07-05
PCT/EP2006/063533 WO2007003521A2 (en) 2005-07-05 2006-06-26 Pyridazine derivatives as 11beta-hydroxysteroid dehydrogenase type 1 inhibitors

Publications (1)

Publication Number Publication Date
UA94052C2 true UA94052C2 (uk) 2011-04-11

Family

ID=36781523

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200801149A UA94052C2 (uk) 2005-07-05 2006-06-26 Похідні піридазину

Country Status (33)

Country Link
US (1) US7678795B2 (uk)
EP (1) EP1904455B1 (uk)
JP (1) JP4787321B2 (uk)
KR (1) KR100979582B1 (uk)
CN (1) CN101528713B (uk)
AR (1) AR054814A1 (uk)
AT (1) ATE520670T1 (uk)
AU (1) AU2006265201C1 (uk)
BR (1) BRPI0613565A2 (uk)
CA (1) CA2612740C (uk)
CL (1) CL2009001936A1 (uk)
CR (1) CR9587A (uk)
CY (1) CY1112401T1 (uk)
DK (1) DK1904455T3 (uk)
EC (1) ECSP088082A (uk)
ES (1) ES2370039T3 (uk)
HK (1) HK1134087A1 (uk)
HR (1) HRP20110808T1 (uk)
IL (1) IL188182A (uk)
MA (1) MA29909B1 (uk)
MX (1) MX2007016352A (uk)
MY (1) MY144209A (uk)
NO (1) NO20076431L (uk)
NZ (1) NZ564260A (uk)
PL (1) PL1904455T3 (uk)
PT (1) PT1904455E (uk)
RS (1) RS51994B (uk)
RU (1) RU2401832C2 (uk)
SI (1) SI1904455T1 (uk)
TW (1) TWI323258B (uk)
UA (1) UA94052C2 (uk)
WO (1) WO2007003521A2 (uk)
ZA (1) ZA200710972B (uk)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7834178B2 (en) 2006-03-01 2010-11-16 Bristol-Myers Squibb Company Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20090264433A1 (en) * 2008-04-21 2009-10-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Triazine Derivatives
WO2009131947A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising pyridazine derivatives
EP2310372B1 (en) 2008-07-09 2012-05-23 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
US8501940B2 (en) * 2008-07-15 2013-08-06 Hoffmann-La Roche Inc. Tetrahydrocinnoline derivatives
US20100022572A1 (en) 2008-07-18 2010-01-28 Kowa Company, Ltd. Novel spiro compound and medicine comprising the same
TW201010975A (en) 2008-08-29 2010-03-16 Kowa Co 1-adamantylazetidin-2-one derivatives and drugs containing same
TW201022210A (en) 2008-10-29 2010-06-16 Kowa Co 1,2-diazetidin-3-one derivatives and drugs containing same
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US20100267706A1 (en) * 2009-04-20 2010-10-21 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
ES2350077B1 (es) 2009-06-04 2011-11-04 Laboratorios Salvat, S.A. Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1.
US8785608B2 (en) 2009-08-26 2014-07-22 Sanofi Crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
KR20160070162A (ko) * 2013-11-05 2016-06-17 에프. 호프만-라 로슈 아게 자가면역 질병의 치료를 위한 RORc 조절인자로서 5,6,7,8-테트라하이드로-5,8-메타노신놀린 유도체
EP3235813A1 (en) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo derivatives
WO2018083105A1 (en) * 2016-11-01 2018-05-11 F. Hoffmann-La Roche Ag Pyridazine derivatives as rorc modulators

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162859A0 (en) * 2002-02-05 2005-11-20 Novo Nordisk As Novel aryl-and heteroarylpiperazines
TWI314455B (en) * 2002-12-10 2009-09-11 Nippon Kayaku Kk 3-phenyl-cinnoline derivatives and anti-tumor agent containing the same
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
WO2004089380A2 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S Pharmaceutical use of fused 1,2,4-triazoles

Also Published As

Publication number Publication date
RU2008103483A (ru) 2009-08-10
CA2612740C (en) 2011-07-26
RU2401832C2 (ru) 2010-10-20
CN101528713A (zh) 2009-09-09
JP4787321B2 (ja) 2011-10-05
MA29909B1 (fr) 2008-11-03
WO2007003521A2 (en) 2007-01-11
NZ564260A (en) 2010-12-24
PL1904455T3 (pl) 2012-01-31
CY1112401T1 (el) 2015-12-09
PT1904455E (pt) 2011-10-04
KR100979582B1 (ko) 2010-09-01
MX2007016352A (es) 2008-03-05
AR054814A1 (es) 2007-07-18
NO20076431L (no) 2008-04-01
RS51994B (en) 2012-04-30
EP1904455B1 (en) 2011-08-17
AU2006265201A1 (en) 2007-01-11
ECSP088082A (es) 2008-02-20
HK1134087A1 (en) 2010-04-16
DK1904455T3 (da) 2011-09-12
SI1904455T1 (sl) 2011-11-30
US7678795B2 (en) 2010-03-16
AU2006265201C1 (en) 2010-12-09
AU2006265201B2 (en) 2010-07-15
IL188182A0 (en) 2008-03-20
ATE520670T1 (de) 2011-09-15
JP2009500370A (ja) 2009-01-08
HRP20110808T1 (hr) 2011-12-31
WO2007003521A3 (en) 2009-02-05
TWI323258B (en) 2010-04-11
CN101528713B (zh) 2013-05-22
BRPI0613565A2 (pt) 2011-01-18
KR20080019272A (ko) 2008-03-03
MY144209A (en) 2011-08-15
EP1904455A2 (en) 2008-04-02
IL188182A (en) 2011-10-31
US20070010519A1 (en) 2007-01-11
CL2009001936A1 (es) 2010-02-19
ZA200710972B (en) 2008-10-29
CA2612740A1 (en) 2007-01-11
CR9587A (es) 2008-01-25
TW200738241A (en) 2007-10-16
ES2370039T3 (es) 2011-12-12

Similar Documents

Publication Publication Date Title
UA94052C2 (uk) Похідні піридазину
TW200608972A (en) Aryl-pyridine derivatives
TW200626558A (en) Indazolone derivatives
TW200616976A (en) Pyrimidine derivatives
TW200740764A (en) Pyrazolone derivatives
MX2010005824A (es) Derivados de aminotiazol.
MX2008016426A (es) Derivados de alquilpiridazina como inhibidores de 11 beta hidroxiesteroide deshidrogenasa tipo 1(11b-hsd 1).
MY139522A (en) New alkyl-pyridines as 11-beta inhibitors for diabetes
IN2012DN03337A (uk)
MY140514A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
MX2007004699A (es) Derivados de indol y bencimidazol.
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
MX2009006598A (es) Derivados de sulfamida como transferasa de carnitina palmitoil del higado (l-cptl).
MX2010005714A (es) Compuestos de piridina.
DE602006021539D1 (en) Morpholine als 5ht2c-agonisten
MX2009003169A (es) Derivados de sulfonamida.
TW200730511A (en) Chroman compounds
IN2012DN01232A (uk)
TW200730510A (en) Chroman compounds
MX2007003105A (es) Derivados de bencimidazol, composiciones que los contienen, sus preparaciones y sus usos i.
MX2009013003A (es) Derivados de piperidina-amida.
IN2012DN01234A (uk)
WO2006004903A3 (en) 1,2-bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
GEP20125563B (en) 2-amino-2-phenylalkanol derivatives, preparation method thereof and pharmaceutical compositions containing same
MX2009001572A (es) Derivados de arilpiperazina y usos de los mismos.